SEATTLE CHILDREN’S signed a letter of intent with Juno Therapeutics Inc. to expand their collaboration to accelerate the availability of T-cell immunotherapy clinical trials for children and adults with brain tumors. The aim of the collaboration is to fast-track clinical implementation with the goal of opening phase I clinical trials within the next two years....
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
